<DOC>
	<DOCNO>NCT00239538</DOCNO>
	<brief_summary>The primary objective study demonstrate telmisartan 80 mg combine hydrochlorothiazide 12.5 mg ( T80/H12.5 ) least effective possibly superior valsartan 160 mg combine hydrochlorothiazide 12.5 mg ( V160/H12.5 ) lower mean ambulatory systolic blood pressure ( SBP ) diastolic blood pressure ( DBP ) last 6 hour 24-hour dose interval end 10-week treatment period mild-to-moderate hypertensive , overweight obese patient type 2 diabetes mellitus</brief_summary>
	<brief_title>SMOOTH - Blood Pressure Control Diabetic/Obese Patients</brief_title>
	<detailed_description>Methodology : Prospective , randomised , open-label , blind end-point , forced-titration , parallel group comparison use Ambulatory Blood Pressure Monitoring ( ABPM ) . Planned/Actual Number Subjects : Enrolled : 1500/2085 ; Randomised : 750/840 ; Complete : 680/752 Diagnosis Main Criteria Inclusion : 1 ) Mild-to-moderate hypertension define baseline mean seat cuff DBP 95 - 109 ( inclusive ) mmHg , and/or SBP 140-179 ( inclusive ) mmHg , baseline 24-hour ABPM mean DBP &gt; = 85 mmHg , and/or SBP &gt; = 130 mmHg . 2 ) Overweight obese define Body Mass Index ( BMI ) &gt; = 27 kg/m2 non-Asians &gt; = 24 kg/m2 Asians 3 ) Type-2 diabetes mellitus . 4 ) At least 30 year age . Duration Treatment : 10 week total : telmisartan ( 80 mg ) valsartan ( 160 mg ) 4 week follow telmisartan ( 80 mg ) plus hydrochlorothiazide ( 12.5 mg ) valsartan ( 160 mg ) plus hydrochlorothiazide ( 12.5 mg ) additional 6 week . Criteria Efficacy : Primary Endpoint : Reductions blood pressure last 6 hour 24-hour dose interval measure ABPM . The primary analysis consist compare telmisartan combine hydrochlorothiazide 80 mg/12.5 mg valsartan combine hydrochlorothiazide 160 mg/12.5 mg end 10-week study use close test procedure first test non-inferiority base SBP ; significant , test non-inferiority base DBP ; significant , test superiority base SBP ; significant , test superiority base DBP . Secondary Endpoints : Statistically great reduction ambulatory blood pressure patient treat telmisartan combine hydrochlorothiazide 80 mg/12.5 mg compare patient treat valsartan combine hydrochlorothiazide 160 mg/12.5 mg end 10-week study measure : 1 ) Changes baseline last 6 hour 24-hour dose interval pulse pressure ; 2 ) Changes baseline 24-hour ABPM mean ( relative dose time ) SBP , DBP , pulse pressure ; 3 ) Changes baseline ABPM mean SBP , DBP , pulse pressure ( relative clock time ) period ( i.e. , morning , daytime , night time ) 24-hour dose interval ; 4 ) Change baseline systolic diastolic blood pressure load 24-hour dosing interval ; 5 ) Percentage patient respond treatment base 24-hour ABPM mean SBP DBP ( relative dose time ) . Statistically great reduction mean seat trough blood pressure patient treat telmisartan combine hydrochlorothiazide 80 mg/12.5 mg compare patient treat valsartan combine hydrochlorothiazide 160 mg/12.5 mg end 10-week study measure : 1 ) Changes baseline mean seat trough SBP DBP determine electronic manual device in-clinic ; 2 ) Percentage patient respond treatment base electronic manual in-clinic trough cuff blood pressure . Evaluation endpoint compare telmisartan combine hydrochlorothiazide 80 mg/12.5 mg valsartan combine hydrochlorothiazide 160 mg/12.5 mg , respectively , include : 1 ) Changes baseline metabolic marker : serum TG , LDL-C , HDL-C , total cholesterol , potassium , fast glucose HbA1C , urine : Na , K , Cl , proteinuria ( measure spot urine protein : creatinine ratio ) ; 2 ) inflammatory marker : serum high sensitive C-reactive protein , serum homocysteine plasma fibrinogen . Criteria Safety : Evaluation adverse event , physical examination , laboratory assessment , pulse rate cuff blood pressure monitoring . Statistical Method : Analysis covariance treatment centre main effect baseline covariate ; Mantel-Haenszel test control centre . Study Hypothesis : Null Hypothesis : The overall mean change baseline automate blood pressure monitor mean blood pressure last 6 hour 24-hour dose interval telmisartan ( 80 mg ) plus hydrochlorothiazide ( 12.5 mg ) less equal valsartan ( 160 mg ) plus hydrochlorothiazide ( 12.5 mg ) . Alternative Hypothesis : The overall mean change baseline automate blood pressure monitor mean blood pressure last 6 hour 24-hour dose interval telmisartan ( 80 mg ) plus hydrochlorothiazide ( 12.5 mg ) great valsartan ( 160 mg ) plus hydrochlorothiazide ( 12.5 mg ) . Comparison ( ) : Telmisartan ( 80 mg ) plus hydrochlorothiazide ( 12.5 mg ) vs. valsartan ( 160 mg ) plus hydrochlorothiazide ( 12.5 mg )</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>1 . Ability provide write informed consent . 2 . Hypertension define mean seat DBP 95109 ( inclusive ) mmHg , and/or SBP 140179 ( inclusive ) mmHg , measure BpTRU electronic manual cuff Visit 2 . 3 . 24hour mean DBP &gt; = 85 mmHg , and/or SBP = 130 mmHg , measure ABPM Visit 3 . 4 . 30 year age great . 5 . Ability stop current antihypertensive therapy disallow medication without risk patient . 6 . Diagnosis type2 diabetes mellitus HbA1C le equal 10 % . 7 . Overweight obese define BMI &gt; = 27 kg/m2 nonAsians &gt; = 24 kg/m2 Asians . 8 . Negative UPT female . 1 . Premenopausal woman , surgically sterile , nursing/pregnant childbearing potential practice acceptable method birth control study . 2 . Night shift worker 3 . Mean sit SBP &gt; = 180 mmHg mean sit DBP &gt; = 110 mmHg visit placebo runin period . 4 . Known suspected secondary hypertension . Hepatic and/or renal dysfunction 5 . Fasting serum glucose &gt; 17 mmol/l ( 300 mg/dl ) visit 2 6 . Bilateral renal artery stenosis , renal artery stenosis solitary kidney , patient dialysis postrenal transplant patient . 7 . Clinically relevant sodium depletion , hypokalaemia hyperkalaemia . 8 . Uncorrected volume depletion . 9 . Primary aldosteronism . 10 . Hereditary fructose intolerance . 11 . Biliary obstructive disorder ( e.g. , cholestasis ) . 12 . Congestive heart failure 13 . Stroke within past six month . 14 . Documented severe obstructive coronary artery disease . 15 . Myocardial infarction , cardiac surgery unstable angina within past three month . 16 . PCI ( percutaneous coronary intervention ) within past three month plan trial period . 17 . Sustained ventricular tachycardia , atrial fibrillation , atrial flutter clinically relevant cardiac arrhythmia . 18 . Hypertrophic obstructive cardiomyopathy , aortic stenosis , hemodynamically relevant stenosis aortic mitral valve . 19 . Patients type1 diabetes mellitus . 20 . Patients previously experience symptom angioedema ACE ARB treatment . 21 . History drug alcohol dependency past six month . 22 . Chronic administration medication know affect blood pressure , except medication allow protocol . 23 . Any investigational drug therapy within past month . 24 . Known hypersensitivity component study drug . 25 . Concurrent use corticosteroid , colestipol cholestyramine resin . 26 . Any clinical condition would allow safe completion protocol . 27 . Inability comply protocol . 28 . Any surgery , time screening , plan take place study period . 29 . History noncompliance prescribe medication .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>